Duchenne Muscular Dystrophy

Sarepta outlines final push for Duchenne gene therapy
BioPharma Dive
Mon, 10/11/21 - 09:52 pm
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Capricor's DMD clinical trial meets primary endpoints
Endpoints
Fri, 09/24/21 - 11:52 am
Capricor
clinical trials
Duchenne Muscular Dystrophy
CAP-1002
8 key clinical trials to watch for the rest of 2021
BioPharma Dive
Mon, 06/21/21 - 11:11 am
clinical trials
Merck
Ridgeback Biotherapeutics
COVID-19
Intellia Therapeutics
transthyretin amyloidosis
Arcus Biosciences
Gilead Sciences
lung cancer
Sanofi
GSK
vaccines
uniQure
Huntington's disease
Mirati Therapeutics
gene editing
Seres Therapeutics
ulcerative colitis
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program
Endpoints
Tue, 06/1/21 - 11:43 am
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy
vamorolone
clinical trials
Sarepta touts clean data for commercial grade Duchenne gene therapy, clearing key hurdle to PhIII
Endpoints
Tue, 05/18/21 - 11:11 am
Sarepta
Duchenne Muscular Dystrophy
clinical trials
gene therapy
Pfizer halts BCMA trial amid safety woes, hit by DMD delay
Fierce Biotech
Tue, 05/4/21 - 10:53 am
Pfizer
BCMA
clinical trials
Duchenne Muscular Dystrophy
elranatamab
fordadistrogene movaparvovec
Sarepta's second-gen Duchenne drug shows signs of topping its first
BioPharma Dive
Mon, 05/3/21 - 10:54 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
gene therapy
GlaxoSmithKline culls early-stage Immunocore med as well as DMD asset in Q1 clear-out
Fierce Biotech
Wed, 04/28/21 - 10:47 am
GSK
oncology
Immunocore
Duchenne Muscular Dystrophy
Is Sarepta Therapeutics Worthy of Redemption?
Motley Fool
Fri, 04/2/21 - 10:52 am
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Entrada raises $116M to take DMD therapy into the clinic
Fierce Biotech
Wed, 03/31/21 - 10:44 am
Entrada Therapeutics
Duchenne Muscular Dystrophy
Solid Bio’s long, troubled slog through the clinic yields promising early data. Can it win back trust?
Endpoints
Mon, 03/15/21 - 11:58 pm
Solid Biosciences
gene therapy
Duchenne Muscular Dystrophy
FDA Approves Third Sarepta Treatment For Duchenne Muscular Dystrophy
BioSpace
Sun, 02/28/21 - 10:15 pm
Sarepta Therapeutics
Amondys 45
Duchenne Muscular Dystrophy
FDA
PTC aims again for FDA review of Duchenne drug despite latest miss
BioPharma Dive
Sat, 02/6/21 - 11:10 pm
PTC Therapeutics
Translarna
Duchenne Muscular Dystrophy
FDA
Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock
Fierce Biotech
Fri, 01/8/21 - 09:30 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
clinical trials
SRP-9001
Pfizer beats Sarepta to the start of first late-stage Duchenne gene therapy trial
BioPharma Dive
Thu, 01/7/21 - 11:36 am
Pfizer
Sarepta Therapeutics
clinical trials
Duchenne Muscular Dystrophy
gene therapy
Sarepta shares first results on next-generation Duchenne drug
BioPharma Dive
Tue, 12/8/20 - 11:13 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-5051
Exondys 51
Could Eli Lilly and Precision BioSciences Make Breakthroughs for DMD?
BioSpace
Fri, 11/20/20 - 11:09 am
Eli Lilly
Precision Biosciences
Duchenne Muscular Dystrophy
Santhera axes half its employees and sees CMO depart after PhIII DMD fail
Endpoints
Mon, 11/2/20 - 10:23 am
Santhera
reorganization
Duchenne Muscular Dystrophy
vamorolone
layoffs
Santhera flunks DMD phase 3, prompting restructuring and withdrawal of approval application
Fierce Biotech
Tue, 10/6/20 - 10:40 am
Santhera Pharmaceuticals
clinical trials
Duchenne Muscular Dystrophy
idebenone
FDA Grants Fast Track Designation to Pfizer's DMD Gene Therapy
BioSpace
Fri, 10/2/20 - 12:41 pm
Pfizer
fast track
FDA
Duchenne Muscular Dystrophy
PF-06939926

Pages